Adverse Drug Event Profile Associated with Anti-dementia Drugs: Analysis of a Spontaneous Reporting Database

• Published in: Pharmazie Vol. 78; no. 5; p. 42
• Main Authors: Kose, E, Yamamoto, T, Tate, N, Ando, A, Enomoto, H, Yasuno, N
• Format: Journal Article
• Language: English
• Published: Germany 01.05.2023
• Subjects: Acetylcholinesterase; Cholinesterase Inhibitors - adverse effects; Donepezil - adverse effects; Drug-Related Side Effects and Adverse Reactions - epidemiology; Galantamine - adverse effects; Humans; Indans - adverse effects; Memantine - adverse effects; Piperidines; Rivastigmine - adverse effects
• DOI: 10.1691/ph.2023.2584
• ISSN: 0031-7144

Adverse drug events (ADEs) rates associated with anti-dementia acetylcholinesterase inhibitors are estimated to be 5%-20% and show a wide range of symptoms. No report has examined whether there is a difference in the anti-dementia drugs' ADEs profile. This study aimed to establish whether anti-dementia drugs' ADEs profile differed. Data was based on the Japanese Adverse Drug Event Report (JADER) database. The reporting odds ratios (RORs) was used to analyze data for ADEs from April 2004-October 2021. The target drugs were donepezil, rivastigmine, galantamine, and memantine. The top ten most frequently occurring adverse events were selected. The association between the RORs and antidementia drug ADEs was evaluated, and compared the distribution rate of expression age related to ADEs and each ADEs' timing of onset due to anti-dementia drugs. The primary outcome was RORs. Secondary outcome were expression age and time-to-onset of ADE associated with anti-dementia drugs. A total of 705,294 reports were analyzed. The adverse events incidence differed. Bradycardia, loss of consciousness, falls, and syncope incidence were significantly diverse. The Kaplan-Meier curve results for the cumulative ADEs incidence showed that donepezil had the slowest onset, while galantamine, rivastigmine, and memantine had approximately the same timing of onset.